ArticleJournal of virus eradication2015
Clinical outcomes and antiretroviral therapy in 'elite' controllers: a review of the literature.
Article in Journal of virus eradication, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed.
- Have We Met Before? Findings on HIV Retesting in Routine Healthcare Settings, Using Eswatini HIV-1 Recent Infection Surveillance Data.Journal of the International AIDS Society · 2026Article
- Immune checkpoint landscape in CD4⁺ T cells stratifies HIV-infected individuals by clinical progression.Immunologic research · 2026Article
- Dual Antiretroviral Therapy-All Quiet Beneath the Surface?Frontiers in immunology · 2021Review
- Review
- Outcomes of immunomodulatory and biologic therapy in people living with HIV.AIDS (London, England) · 2020Article
- Targeting Inflammation to Reduce Atherosclerotic Cardiovascular Risk in People With HIV Infection.Journal of the American Heart Association · 2020Review
- HIV-1 elite controllers: an immunovirological review and clinical perspectives.Journal of virus eradication · 2019Article
- Why Everyone (Almost) with HIV Needs to Be on Treatment: A Review of the Critical Data.Infectious disease clinics of North America · 2019Review
- Natural control of HIV infection in young women in South Africa: HPTN 068.HIV clinical trials · 2018Article
- Lack of Virological Suppression Among Young HIV-Positive Adults in Botswana.Journal of acquired immune deficiency syndromes (1999) · 2018Article
- Undisclosed antiretroviral drug use in Botswana: implication for national estimates.AIDS (London, England) · 2018Article
- HIV prevention strategies and risk of infection: a model-based analysis.Epidemiology and infection · 2018Article
- Serious Non-AIDS Conditions in HIV: Benefit of Early ART.Current HIV/AIDS reports · 2018Review
- High HIV-1 RNA Among Newly Diagnosed People in Botswana.AIDS research and human retroviruses · 2018Article
- High Plasma Levels of sTNF-R1 and CCL11 Are Related to CD4+ T-Cells Fall in Human Immunodeficiency Virus Elite Controllers With a Sustained Virologic Control.Frontiers in immunology · 2018Article
- Mechanisms of Virologic Control and Clinical Characteristics of HIV+ Elite/Viremic Controllers.The Yale journal of biology and medicine · 2017Review
- Factors Associated with the Size of HIV DNA Reservoir.Chinese medical journal · 2017Review
- Prospecting for an HIV vaccine.Tropical diseases, travel medicine and vaccines · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Elite controllers naturally suppress HIV viraemia below the level of detection using standard methods, but demonstrate persistent inflammation and low-level viraemia that is detectable via ultrasensitive assays. These factors may contribute to an increased risk of non-AIDS-related morbidity and mortality among elite controllers. Data suggest that cardiovascular disease may be of particular concern in elite controllers, as evidenced by an increased burden of subclinical cardiovascular disease upon radiographic screening and an elevated rate of hospitalisations for cardiovascular disease as compared to non-controllers who are treated with antiretroviral therapy (ART). Widespread use of ART among non-controllers has led to significant declines in morbidity and mortality, but guidelines are generally silent on the role of ART in the care of elite controllers. Multiple small studies have demonstrated that laboratory markers of inflammation, immune activation and HIV burden improve after initiation of ART in elite controllers. Clinicians must consider these potential benefits of ART when deciding whether to initiate treatment in asymptomatic elite controllers.
Identifiers
27123315PMC4844069What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.